Clin Oncol | Volume 7, Issue 1 | Research Article | Open Access

Impact of Daratumumab on Anti-HLA Antibodies Level in Patients with Multiple Myeloma, a Role in Transplantation?

Floriane Theves1, David Kheav3, Alexis Talbot1, Marie-Noelle Peraldi2, Camille Villesuzanne1, Stephanie Harel1, Bruno Royer1, Anne-Claire Lepretre4, Maryvonnick Carmagnat3, Jean-Luc Taupin3 and Bertrand Arnulf1*

1Department of Immunohematology, APHP University of Paris, France
2Department of Nephrology and Transplantation, APHP University of Paris, France
3Immunology Laboratory, APHP University of Paris, France
4Department of Transfusion, Etablissement Français Du Sang, France

*Correspondance to: Bertrand Arnulf 

Fulltext PDF


Daratumumab, a humanized anti-CD38 monoclonal antibody, has demonstrated anti-plasma cell activity alone and in combination with other drugs in Multiple Myeloma (MM) and in light chain Amyloidosis (AL). Allogenic anti-Human Leukocyte Antigen (HLA) antibodies are frequently encountered in patients awaiting kidney transplantation, complicating the access to a compatible
transplant and represent a major risk factor of humoral rejection. Durably removing the antibodies or eliminating the producing cells is an objective that is currently out of reach. The objectives of our study were to evaluate the frequency of anti-HLA antibodies in MM and AL patients, and to determine the effect of daratumumab on them.
Eligible patients with diagnosed MM or AL were selected (n=182), among whom 84 had anti HLA antibodies (46%). Forty-nine patients (45 MM and 4 AL) were retrospectively included.
Patients were treated with a combination of an alkylating agent, an Immunomodulatory imide Drug (IMiD), a Proteasome inhibitor, with (n=22) or without (n=22) daratumumab. Five patients received daratumumab alone. Treatment with daratumumab lowered anti-HLA antibodies in 85% (23/27) of cases including complete loss in 56% of cases (15/27) compared to 77% (17/22) and 45%
(10/22) respectively, p=0.8.
This study couldn’t find a statistic impact of daratumumab to lower HLA antibody in this cohort. The association with chemotherapy could be an important bias and this hypothesis will be evaluated in ongoing studies enrolling patients undergoing kidney transplantation.


Anti-HLA antibodies; Daratumumab; Kidney transplantation; Multiple myeloma


Theves F, Kheav D, Talbot A, Peraldi M-N, Villesuzanne C, Harel S, et al. Impact of Daratumumab on Anti-HLA Antibodies Level in Patients with Multiple Myeloma, a Role in Transplantation?. Clin Oncol. 2022;7:1939..

Subscribe to Our Newsletter